reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The process for class 1 inteins begins with an N-O or N-S shift when the side chain of the first residue (a serine, threonine, or cysteine) of the intein portion of the precursor protein nucleophilically attacks the peptide bond of the residue immediately upstream (that is, the final residue of the N-extein) to form a linear ester (or thioester) intermediate. A transesterification occurs when the side chain of the first residue of the C-extein attacks the newly formed (thio)ester to free the N-terminal end of the intein. This forms a branched intermediate in which the N-extein and C-extein are attached, albeit not through a peptide bond. The last residue of the intein is always an asparagine (Asn), and the amide nitrogen atom of this side chain cleaves apart the peptide bond between the intein and the C-extein, resulting in a free intein segment with a terminal cyclic imide. Finally, the free amino group of the C-extein now attacks the (thio)ester linking the N- and C-exteins together. An O-N or S-N shift produces a peptide bond and the functional, ligated protein. Class 2 inteins have no nucleophilic first side chain, only an alanine. Instead, the reaction starts directly with a nucleophilic displacement, with the first residue of the C-extein attacking the peptide carboxyl on the final residue of the N-extein. The rest proceeds as usual, starting with Asn turning into a cyclic imide. Class 3 inteins have no nucleophilic first side chain, only an alanine, yet they have an internal noncontiguous "WCT" motif.
It was estimated in 2017 that nearly one in three persons globally had at least one form of malnutrition: wasting, stunting, vitamin or mineral deficiency, overweight, obesity, or diet-related noncommunicable diseases. Undernutrition is more common in developing countries. Stunting is more prevalent in urban slums than in rural areas. Studies on malnutrition have the population categorised into different groups including infants, under-five children, children, adolescents, pregnant women, adults and the elderly population. The use of different growth references in different studies leads to variances in the undernutrition prevalence reported in different studies. Some of the growth references used in studies include the National Center for Health Statistics (NCHS) growth charts, WHO reference 2007, Centers for Disease Control and Prevention (CDC) growth charts, National Health and Nutrition Examination Survey (NHANES), WHO reference 1995, Obesity Task Force (IOTF) criteria and Indian Academy of Pediatrics (IAP) growth charts. In 2023, an estimated 28.9 percent of the global population – 2.33 billion people – were moderately or severely food insecure.
The conquest of Cyprus by the Anglo-Norman forces of the Third Crusade opened a new chapter in the history of the island, which would be under Western European domination for the following 380 years. Although not part of a planned operation, the conquest had much more permanent results than initially expected. In April 1191, Richard the Lion-hearted left Messina with a large fleet in order to reach Acre. But a storm dispersed the fleet. After some searching, it was discovered that the boat carrying his sister and his fiancée Berengaria was anchored on the south coast of Cyprus, together with the wrecks of several other ships, including the treasure ship. Survivors of the wrecks had been taken prisoner by the island's despot Isaac Komnenos. On 1 May 1191, Richard's fleet arrived in the port of Limassol on Cyprus. He ordered Isaac to release the prisoners and the treasure. Isaac refused, so Richard landed his troops and took Limassol. Various princes of the Holy Land arrived in Limassol at the same time, in particular Guy de Lusignan. All declared their support for Richard provided that he support Guy against his rival Conrad of Montferrat. The local barons abandoned Isaac, who considered making peace with Richard, joining him on the crusade, and offering his daughter in marriage to the person named by Richard. But Isaac changed his mind and tried to escape. Richard then proceeded to conquer the whole island, his troops being led by Guy de Lusignan. Isaac surrendered and was confined with silver chains, because Richard had promised that he would not place him in irons.
α2-Macroglobulin (α2M) or alpha-2-macroglobulin is a large (720 KDa) plasma protein found in the blood. It is mainly produced by the liver, and also locally synthesized by macrophages, fibroblasts, and adrenocortical cells. In humans it is encoded by the A2M gene. α2-Macroglobulin acts as an antiprotease and is able to inactivate an enormous variety of proteinases. It functions as an inhibitor of fibrinolysis by inhibiting plasmin and kallikrein. It functions as an inhibitor of coagulation by inhibiting thrombin. α2-macroglobulin may act as a carrier protein because it also binds to numerous growth factors and cytokines, such as platelet-derived growth factor, basic fibroblast growth factor, TGF-β, insulin, and IL-1β. No specific deficiency with associated disease has been recognized, and no disease state is attributed to low concentrations of α2-macroglobulin. The concentration of α2-macroglobulin rises 10-fold or more in the nephrotic syndrome when other lower molecular weight proteins are lost in the urine. The loss of α2-macroglobulin into urine is prevented by its large size. The net result is that α2-macroglobulin reaches serum levels equal to or greater than those of albumin in the nephrotic syndrome, which has the effect of maintaining oncotic pressure.
Sources: en.wikipedia.org
Ultramicrotomy is a method of preparing extremely thin sections for transmission electron microscope (TEM) analysis. Tissues are commonly embedded in epoxy or other plastic resin. Very thin sections (less than 0.1 micrometer in thickness) are cut using diamond or glass knives on an ultramicrotome.
== Structure == Type VII collagen is composed of three main domains in the following order: a non-collagenous domain, abbreviated NC-1; a collagenous domain; and a second non-collagenous domain, NC-2. The NC-1 domain has a cartilage matrix protein (CMP), nine fibronectin III (FNIII)-like subdomains, and a von Willebrand Factor A-like subdomain (VWFA1); a notable segment in the NC-2 domain is analogous to a Kunitz protease inhibitor molecule.
== Career == Macor began his industrial career at Pfizer in 1986, where he was a co-inventor of eletriptan, a triptan marketed as Relpax for the acute treatment of migraine. Eletriptan was approved by the FDA in 2002. He later joined Bristol-Myers Squibb in 1997, where he served as executive director of neuroscience chemistry. At Bristol-Myers Squibb, he was a co-inventor in the program that produced the CGRP receptor antagonists rimegepant and zavegepant, which were subsequently developed by Biohaven Pharmaceuticals and approved by the FDA in 2020 and 2023, respectively, for the treatment of migraine. He is also a co-inventor of sparsentan, a dual endothelin and angiotensin II receptor antagonist developed by Travere Therapeutics and approved by the FDA in 2023 for the reduction of proteinuria in adults with IgA nephropathy. Macor’s work at Bristol-Myers Squibb also included the company’s Alzheimer’s disease program, where he contributed to the discovery of avagacestat (BMS-708163), a γ-secretase inhibitor that advanced to Phase 2 clinical trials before development was discontinued. Macor is an author on more than 220 peer-reviewed publications and a named inventor on 150 issued U.S. patents.
Sources: en.wikipedia.org
The recommended daily intakes for children aged three years and older is 10% to 20% higher than adult levels and those for infants can be as much as 150% higher in the first year of life. Cysteine (or sulfur-containing amino acids), tyrosine (or aromatic amino acids), and arginine are always required by infants and growing children. Methionine and cysteine are grouped together because one of them can be synthesized from the other using the enzyme methionine S-methyltransferase and the catalyst methionine synthase. Phenylalanine and tyrosine are grouped together because tyrosine can be synthesized from phenylalanine using the enzyme phenylalanine hydroxylase.
=== National service === Heseltine had transferred his articles to a partner at a smaller firm of accountants located off Haymarket, feeling that this would allow him more chance of hands-on involvement in the affairs of the firms whose books he examined, rather than being a cog in a bigger machine. It took him three attempts and special coaching to pass his intermediate exams, and he had little immediate prospect of passing his accountancy finals. He also estimated that he was earning more from his property business than the partner to whom he was articled. With the expiry of his articles in January 1958 he could no longer avoid conscription into National Service. Heseltine later wrote that he admired the military, for his father had been a lieutenant-colonel in the Royal Engineers in the Second World War and active in the Territorial Army thereafter, but that he had felt that his business career was too important to be disrupted. He and his father had taken the precaution of arranging interviews to increase his chances of attaining an officer's commission in case he had to serve. He had been lucky not to be called up for the Korean War in the early 1950s or the Suez Crisis in 1956; and in the final years of National Service, already due for abolition by 1960, an effort was made to call up men who had so far managed to postpone service. Despite having almost reached maximum call-up age, recently reduced from thirty to twenty-six, Heseltine was conscripted into the Welsh Guards in January 1959.
Human and mouse protein kinases in UniProt: classification and index Kinase.Com: Genomics, evolution and large-scale analysis of protein kinases (non-commercial). KinMutBase: A registry of disease-causing mutations in protein kinase domains Archived 2022-06-15 at the Wayback Machine KLIFS (Kinase-Ligand Interaction Fingerprints and Structures) Database -- analysis of kinase structures and kinase-inhibitor interactions KinCore: the Kinase Conformation Resource: A web resource for protein kinase sequence, structure and phylogeny Kinomer: A multilevel HMM library for the classification and functional annotation of eukaryotic protein kinases.
DMT can rarely cause hallucinogen-induced psychotic disorder (HIPD). HIPD is a type of substance-induced psychosis. The symptoms of HIPD are psychosis with paranoia, delusions, hallucinations, disorganized thinking, or insomnia that persist beyond the initial effects of the drug. HIPD due to psychedelics is most commonly associated with LSD, but may be caused by DMT as well. Hallucinogen-induced psychotic disorder is a medical emergency. Without treatment, the psychosis can persist for weeks or months. The treatment is an atypical antipsychotic medication such as aripiprazole, quetiapine, olanzapine, or risperidone. People with a personal or family history of mental illness are at the highest risk for hallucinogen-induced psychotic disorder. The condition occurs in fewer than 1% of people with psychedelics.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.